

Netherlands Economic Mission to Boston

4 - 9 June 2023



Netherlands

Index

Foreword Ministers	4
Foreword Business Delegation Leader	5

The Netherlands

Map of the Netherlands	7
Introducing the Netherlands	8
What more does the Netherlands have to offer?	9
Facts & Figures	10
Massachusetts and the Netherlands	11

Company profiles

Amgen	14
Amsterdam UMC	15
Ardena Bioanalysis	16
Arega Medical	17
AstraZeneca	18
BioConnection	19
Bi/ond	20
Biotech Booster	21
Dutch Association Innovative Medicines	22
FAST	23
Health~Holland	24
HollandBIO	25
Hybridize Therapeutics	26
Intravacc	27
Janssen Biologics	28
Janssen-Cilag	29
Kadans Science Partner	30
Leiden Bio Science Park	31
Leiden University	32
Life Cooperative	33
Loyens & Loeff	34
MSD	35
Municipality Oss	36
NanoCell Therapeutics	37
Neolook Solutions	38

Company profiles	Netherlands Foreign Investment Agency	39	
	Nostics	40	
	Novartis	41	
	Ofichem Group	42	
	Organon	43	
	Orgonex	44	
	PD-value	45	
	Philikos	46	
	Pivot Park / PPSC	47	
	Poonawalla Science Park	48	
	Protinhi Therapeutics	49	
	Radboud university medical center	50	
	Rijksmuseum Boerhaave	51	
	Roche Nederland	52	
	Rotterdam Square	53	
	Sanofi	54	
	ShanX Medtech	55	
	SRC-Search	56	
	TASK Research International	57	
	THINC. Healthcare	58	
	TNL	59	
	TNO	60	
	University Medical Center Groningen	61	
	UMC Utrecht, U-TRIAL & THINC Healthcare	62	
	VivArt-X	63	
	VNO-NCW	64	
	Official delegation & Contact details	Ministry of Economic Affairs & Climate Policy	66
		Ministry of Health, Welfare and Sport	68
		Netherlands Enterprise Agency	69
Netherlands Innovation Network		70	
Consulate General of the Kingdom of the Netherlands in New York		70	

Foreword



It is our great pleasure to welcome you to our trade mission to Boston, dedicated to Life Sciences & Health.



One-third of the Netherlands' wealth is earned beyond our borders. The Dutch government is proud of our business and research community and its capacity for innovation. This mission to Boston comes at a crucial time, when we are facing major challenges and good transatlantic relations are essential to the Netherlands' security and prosperity. Now, more than ever, we must join forces and use our gift for innovation to face these challenges.

The Greater Boston area is the world's capital of the life sciences industry. It's home to more than 1,000 biotechnology companies, ranging from startups to billion-dollar pharmaceutical companies. The many world leading universities in the area give the region a large network of scientists and an excellent talent pipeline. This means that Boston is full of economic opportunities for collaboration and investment between American and Dutch companies and knowledge institutions.

This mission is a way of showcasing the strength of Dutch companies and organizations in the Life Sciences & Health sector. It is an honour to lead this trade mission together.

Micky Adriaansens

Minister for Economic Affairs and Climate Policy

Ernst Kuipers

Minister for Health, Welfare and Sport

Foreword



Welcome to the Life Sciences mission to Boston. It is a great privilege and pleasure to be the business delegation leader of the visit of Minister of Economic Affairs and Climate Policy, Micky Adriaansens and Minister of Health, Welfare and Sport, Ernst Kuipers, to the BIO International Convention. Their joint participation highlights the exciting opportunities and strong ties between the Netherlands and Massachusetts in the field of life sciences.

As two world-renowned hubs of innovation and research, the Netherlands and Massachusetts share a long history of collaboration in many areas, including life sciences. In fact, the ties between the two regions date back centuries, with the Dutch playing an integral role in the early settlement of Massachusetts. Today, the strong connections between the two regions continue to flourish, fueled by a shared commitment to advancing the frontiers of science and technology.

The Netherlands is a global leader in life sciences, with a thriving ecosystem of startups, research institutions, and established companies. The country is home to a highly talented workforce, cutting-edge research facilities, and a supportive government that fosters innovation and entrepreneurship. Similarly, Massachusetts is renowned for its vibrant life sciences community, which includes world class universities, top research organizations and the world's best biotech firms. Together these two regions are a force to be reckoned with, driving innovation and discovery in the life sciences industry.

The Life Sciences mission from the Netherlands to Boston in the presence of two ministers opens doors for Dutch life sciences companies to connect with their counterparts in Massachusetts and explore new business opportunities. It offers the possibility for Dutch participants to expand their reach and establish a presence in one of the world's most dynamic life sciences ecosystems. Likewise, we anticipate that this visit will provide valuable insights to our counterparts in Massachusetts about the Netherlands as Europe's connected life science & health metropolis.

We look forward to further solidifying the bond between our two regions and express the strong belief that by collaboration and innovation, we can drive the future of life sciences, in the interest of sustainable healthcare, of long-term economic growth, and last but certainly not least, of patients.

Hans Schikan

Business Delegation Leader, Top Team Life Sciences & Health



Map of the Netherlands

Locations

- | | |
|--|----------------|
| 1. Amsterdam
(and Airport Schiphol) | 9. Haarlem |
| 2. Arnhem | 10. The Hague |
| 3. Assen | 11. Leeuwarden |
| 4. Breda | 12. Lelystad |
| 5. 's Hertogenbosch | 13. Maastricht |
| 6. Eindhoven | 14. Middelburg |
| 7. Enschede | 15. Rotterdam |
| 8. Groningen | 16. Utrecht |
| | 17. Zwolle |





Introducing the Netherlands

How do the Dutch make a difference?

Through their interactive approach to finding innovative solutions to the big challenges facing the world today. The Dutch way of thinking and working has been shaped by centuries of living in the low-lying delta of the Netherlands. Through the ages, the Dutch have joined forces to find ingenious ways to tackle challenges like water, urbanisation, energy, food, health and security. By being inventive, pragmatic and open to new challenges, the Dutch have created a flourishing and resilient land.

The Netherlands is a constantly evolving ecosystem of cities, industry, agriculture and nature, all integrated through smart infrastructure. It is a source of knowledge and experience that the Dutch are keen to share with others. Learning from the past to create a better future. Together, seeking sustainable solutions for the most liveable world.

Europe's connected Life Sciences & Health metropolis



What more does the Netherlands have to offer?

#1

Global
Connectedness
Index (DHL)

#1

Quality of Life
Index (NUMBEO)

#1

Most research
papers published
per capita in EU
(SJR)

#2

Healthcare in high-
income nations
(Commonwealth
Fund)

#2

Growth Promise
Indicator
(KPMG)

#2

Global
Entrepreneurship
Monitor (GEM)

#3

Digital Economy
and Society
Index (European
Commission)

#4

Global
Competitiveness
Report (WEF)

#5

Global Innovation
Leader (WIPO)

Facts & Figures

Official name:
Kingdom of the
Netherlands

Capital:
Amsterdam

Seat of government:
The Hague

Form of government:
Parliamentary
democracy (cabinet
of Prime Minister
and Ministers) within
a constitutional
monarchy

Head of State:
His Majesty King
Willem-Alexander,
King of the
Netherlands, Prince
of Orange-Nassau

Location:
Western Europe,
bordering Germany,
Belgium and the
North Sea

Administrative structure:
The kingdom consists of four entities.
The Netherlands and three territories in the
Caribbean: Aruba and Curaçao and St. Maarten

Special municipalities:
The overseas islands of Bonaire, Saba and
St. Eustatius, all three of which are situated in the
Caribbean

Surface area:
41,545 km²

Number of inhabitants (2022):
17,564,623

Monetary Unit:
Euro

Languages:
Dutch, Frisian and on the
overseas islands also
English and Papiaments

GDP per capita
(World Bank, 2021):
58,061 US dollars

Number of provinces:
12

Number of inhabitants
per km2 (2022):
423

Unemployment rate
(CBS, 2022):
3.3%

English speaking Dutch
people:
90%




Massachusetts and the Netherlands

During the economic mission of Prime Minister Rutte and Minister Bruins of VWS to Boston in 2019, a historic agreement was made to enhance collaboration in the life sciences industry between the Netherlands and Massachusetts. As a result, a comprehensive program was designed to boost investments, businesses, research, and talent between the two regions. With Health~Holland and Massachusetts Life Sciences Center leading the charge, this Program of Cooperation is supported by a group of exceptional organizations, including the Termeer Foundation, HollandBIO, MassBio, and the Association of Innovative Medicines.

Since then, several initiatives, including three life sciences-themed missions, a virtual workshop on clinical development, and an investment conference for Dutch startups, have been launched, all with great success. The Termeer Foundation is proud to sponsor the third Henri Termeer Transatlantic Connections Award, which honors the legacy of a visionary Dutchman and former CEO of Genzyme who

played a pioneering role in the biotech industry in Massachusetts and beyond. This award supports young biotech entrepreneurs. The collaboration between the Netherlands and Massachusetts is an opportunity to build on the legacy of Termeer and strengthen ties in the life sciences industry.

In the short term, these initiatives have already delivered excellent results, with multiple Dutch participants establishing partnerships and collaborations in Massachusetts, and two participants choosing to establish their European headquarters in the Netherlands. This trade mission to Boston marks the next milestone in this exciting collaboration. It offers the delegation a prime opportunity to leverage Boston's dynamic life sciences ecosystem while showcasing the Netherlands' world-class life sciences industry.



* MassBio's Industry Snapshot report, 2022. <https://www.massbio.org/industry-snapshot/>

† U.S. News' annual Best Hospitals Honor Roll, a list of the top 20 hospitals nationwide.

‡ February 2023: <https://www.epmscientific.com/blog/2023/02/boston-is-now-the-largest-biotech-hub#:~:text=Boston%20is%20home%20to%20the%20most%20concentrated%20companies%20and%20start%20ups.>

§ Bidbook 2023

¶ <https://hospitals.webometrics.info/en/Europe>

Company profiles

Amgen
Amsterdam UMC
Ardena Bioanalysis
Arega Medical
AstraZeneca
BioConnection
Bi/ond
Biotech Booster
Dutch Association Innovative Medicines
FAST
Health~Holland
HollandBIO
Hybridize Therapeutics
Intravacc
Janssen Biologics
Janssen-Cilag
Kadans Science Partner
Leiden Bio Science Park
Leiden University
Life Cooperative
Loyens & Loeff
MSD
Municipality Oss
NanoCell Therapeutics
Neolook Solutions
Netherlands Foreign Investment Agency
Nostics
Novartis
Ofichem Group
Organon
Orgonex
PD-value
Philikos
Pivot Park / PPSC
Poonawalla Science Park
Protinhi Therapeutics
Radboud university medical center
Rijksmuseum Boerhaave
Roche Nederland
Rotterdam Square
Sanofi
ShanX Medtech
SRC-Search
TASK Research International
THINC. Healthcare
TNL
TNO
University Medical Center Groningen
UMC Utrecht, U-TRIAL & THINC Healthcare
VivArt-X
VNO-NCW



Amgen



Carolina Correa
General Manager
+31 6 2509 5680
ccorre03@amgen.com



Joep Rijnierse
Medical Director
+31 6 1136 8980
joepr@amgen.com

Amgen is an international biotechnology company that makes an active contribution to better care. Amgen scientists have been developing innovative therapies for patients with serious illnesses since 1980. Our product portfolio encompasses the following therapeutic areas: oncology, hematology, bone diseases, inflammation, and cardiovascular diseases.

Amgen is active in around 100 countries worldwide. Amgen Europe BV has been located in Breda since 1997. At this site, Amgen medicines are labeled, provided with patient information leaflets, packaged and distributed throughout Europe and to a growing number of countries in other parts of the world. The Dutch sales organization Amgen Netherlands BV is also located in Breda. It is responsible for the availability of our medicines and clinical trials in the Netherlands.

Amgen has built up an excellent, worldwide reputation in the area of biologics - medicines made using biotechnological techniques. Amgen supplies high-quality medicines and focuses primarily on patients with conditions for which few or no treatment options exist. We are committed to ensuring the best possible outcomes for patients and are working together with our partners inside and outside the healthcare sector to create a better future.



Amgen Nederland
Minervum 7061
4817 ZK Breda
The Netherlands
www.amgen.nl



Amsterdam UMC



Frederique Bambach

Senior Staff Advisor
Valorisation & Program
Manager Urban Dx
+31 6 2301 7670
[f.n.bambach@
amsterdamumc.nl](mailto:f.n.bambach@amsterdamumc.nl)

Amsterdam UMC is a leading medical center that combines complex high-quality patient care, innovative scientific research, and education of the next generation health care professionals. Since the merger of the two academic hospitals AMC and VUmc to form Amsterdam UMC, over 16,000 people now work together at the two locations to provide excellent and accessible care.



Mark Mizee

Business Development
Manager Amsterdam
Neuroscience - ADORE
+31 6 5759 9295
[m.r.mizee@
amsterdamumc.nl](mailto:m.r.mizee@amsterdamumc.nl)

Amsterdam UMC Research brings together opinion leading academic research in the field of Health & Life Sciences developed in the Amsterdam region. In doing so - and on the authority of the two medical centers and the two universities - Amsterdam now has eight alliance research institutes, each with dedicated expertise and focused on particular disease indications. Foremost, the Amsterdam UMC is known for its unique expertise and facilities to perform translational research, from bench to bed and vice versa, which has a strong base in our academic history. This concentration of expertise makes the centre a breeding ground for fruitful public-private collaborations and venture building.



Amsterdam UMC

De Boelelaan 1117 / 1118
1081 HV Amsterdam
The Netherlands
www.amsterdamumc.org

ARDENA

Bioanalysis



Melloney Dröge

Managing Director

+31 6 4933 4578

[melloney.droge@](mailto:melloney.droge@ardena.com)

ardena.com

Ardena Bioanalysis

At Ardena Bioanalysis, we offer a full range of bioanalytical services, from non-regulated early drug discovery to regulated preclinical and clinical phases (Phases I-IV).

In our GLP and GCP compliant laboratory (Assen, The Netherlands), the focus is on state-of-the-art quantitative bioanalysis. For any bioanalytical inquiry, regardless of your analyte, a dedicated method development team solves the most complex bioanalytical challenges in any thinkable biological matrix. With advanced equipment, specialized PK, immunogenicity and biomarker methods are developed and analytes of interest are detected down to the required quantification level.

We offer solutions for all types of drug products and biomarkers, from small molecules to proteins including antibodies, antibody drug conjugates, oligonucleotides, vaccines and nanoparticles.

Experienced in LC-MS/MS and ligand binding assays, specialized in immunogenicity analysis, and with an in-house flow-cytometry facility, we are the lead partner for your drug's assay development and assay validation. Our bioanalytical services streamline regulatory approval.



Ardena Bioanalysis

WA Scholtenstraat 7

9403 AJ Assen

The Netherlands

<https://ardena.com>



Teun Grooters
Chief Executive Officer
+31 6 1589 5730
teun.grooters@arega.com

Arega Medical

Arega Medical, is the leading R&D healthcare company that focusses on identification, development and commercialization of repurposed drugs for untreatable diseases. We have a diversified clinical late-stage R&D portfolio of repurposed drugs in high unmet need diseases.

We aim to address the society need for sustainable healthcare as well as patient's needs for effective, safe and affordable therapies.

We have the conviction and the vision to disrupt the pharmaceutical market.

Repurposed drugs offer a more efficient and cost-effective development path. We believe that the savings this brings to society, should be fed into the healthcare system. Our promise is socially responsible pricing to support sustainable healthcare.

Precision medicine by network pharmacology is a revolution in medicine. Artificial intelligence allows mapping of underlying disease mechanisms and design of targeted drug combinations, treating the underlying disease processes instead of merely providing symptom relief. By combining drugs with companion diagnostics, we will be able to offer precision treatments to patients suffering from untreatable complex diseases.



Arega Medical
Verlengde Poolseweg 16
4818 CL Breda
The Netherlands
www.aregamedical.com



AstraZeneca



Martijn Bax

Country President
The Netherlands
+31 6 1037 9096
martijn.bax@astrazeneca.com
astrazeneca.com

At AstraZeneca we are transforming healthcare for billions of people. As the burden of disease grows and the population ages, the health needs of many remain unmet. Empowered by digital, data, and AI, science is accelerating our understanding of disease, our ability to predict success and our delivery of life changing medicines.

Globally over 83,000 colleagues work together to create novel, more environmentally friendly therapies and vaccines and help people with chronic diseases live better lives.



Ad Antonisse

Director Market Access &
External Affairs
+31 6 5350 6394
ad.antonisse@astrazeneca.com
astrazeneca.com

We work ethically and sustainably, rapidly becoming carbon negative, supporting the resilience of healthcare systems and increasing access to healthcare for patients. We believe that the health of people, society, and planet are interconnected.

We have a balanced presence across regions and a diversified portfolio, with a strong focus on oncology, respiratory, immunology, cardiac, metabolic and infectious disease and rare disease. With a turnover over \$44B (2022), we invest almost \$10B annually (2022) in research and development. By 2030, we expect to launch at least 15 new medicines.



AstraZeneca

Prinses Beatrixlaan 582
2595 BM The Hague
The Netherlands
+31 79 363 2222
www.astrazeneca.nl

Our Dutch headquarters are situated in The Hague. In addition, over 100 colleagues work in our fill & finish location in Nijmegen. In Oss, about 100 scientists work in our European R&D hub for haematology research.

BIO-CONNECTION

BioConnection



Alexander Willemse

CEO

+31 6 2853 0280

[alexander.willemse@
bioconnection.eu](mailto:alexander.willemse@bioconnection.eu)

BioConnection is a GMP contract manufacturer for the production of sterile drug products in vials or syringes. Our state-of-the-art GMP manufacturing facility in Oss, The Netherlands is EMA and US-FDA certified and we have more than 15 years of experience. We can handle liquid products (including suspensions) and freeze dried products in batch sizes ranging from a few hundred vials per batch (personalized medicine purposes) up to 150,000 vials per batch (commercial productions).

We offer complete drug product service packages including drug product development, filling and freeze drying, technology transfers, scale-up, validation programs, analytical support, stability studies, regulatory dossier support, label & pack (incl. serialization) and final GMP release.



Dennis Link

Director Business
Development

+31 6 8334 5359

[dennis.link@
bioconnection.eu](mailto:dennis.link@bioconnection.eu)



BioConnection

Kloosterstraat 9

5349 AB Oss

The Netherlands

www.bioconnection.eu



Cinzia Silvestri
CEO and Co-founder
+31 6 2631 7805
cinzia@biondteam.com

Bi/ond

Bi/ond is at the forefront of the emerging field of engineered microchips for biological applications. Our organ-on-chip technology represents a game-changing innovation that has the potential to transform the way we develop and test new drugs.

The convergence of biology and engineering has opened up exciting new avenues for biomedical research. Our microfluidic chips enable researchers to nourish, stimulate, and monitor human cells in a way that closely mimics the in vivo environment, providing a physiologically relevant model for drug development and testing.

At Bi/ond, we believe that personalized medicine is the future of healthcare. Every person is unique, and our medicines should reflect that. However, current drugs often fail due to interpersonal variation. Our technology solves this problem by providing a platform for easy development and testing of new drugs considering individual differences.

Not only does our technology have the potential to reduce the need for animal testing in research and pharma R&D, but it also represents a step forward in the fight against diseases such as muscular dystrophies and cancer. Our model has already proven to faithfully mimic the in vivo response to different anti-cancer drugs, and can be used to test the effect of drugs on patient tissues, including tumor tissue and heart- and skeletal muscle.



Bi/ond
Molengraaffsingel 10,
2629 JD Delft
The Netherlands
www.gobiond.com



Nettie Buitelaar
Managing Director
+31 6 1002 6742
[nettie.buitelaar@
biotechbooster.nl](mailto:nettie.buitelaar@biotechbooster.nl)

Biotech Booster

Biotech Booster is a Dutch national program to stimulate commercialization of biotechnology research from academia and small industry. The program will run from 2022 – 2031 and is financed by the National Growth Fund with a subsidy of ~ € 250M, to which cofinancing from partners will be added.

The Biotech Booster program will finance extra biotech business developers for technology transfer offices of universities and network developers for universities of applied sciences. Applicants can submit projects that can be financed at several levels: level 1 for proof of principle (max €200k) and level 2 for proof of concept (max €1.9M). Level 3 will be the 'scale-out' phase.

The most important new element of Biotech Booster is the joint involvement of academia and entrepreneurs. From day 1, projects will be advised by entrepreneurs as well and negotiations for spinning out will be done by a team consisting of experienced entrepreneurs and representatives of the project origin, bespoke to the specific project.

With these tools we will strengthen and accelerate the commercialisation of the wealth of biotechnology R&D that is generated in our country.

Biotech Booster
c/o VU
De Boelelaan 1105
1081 HV Amsterdam
The Netherlands
www.biotechbooster.nl

Dutch Association Innovative Medicines



Marco Frenken

Chairman of the Board
at Dutch Association
Innovative Medicines &
Country Manager at Lilly
Netherlands

+31 6 5382 2969

frenken_marco@lilly.com



Erwin Vermeulen

Project Leader Business
Climate & Innovation

+31 6 1360 6315

[e.vermeulen@innovatieve
genesmiddelen.nl](mailto:e.vermeulen@innovatieve
genesmiddelen.nl)



Dutch Association Innovative Medicines

Prinses Beatrixlaan 548-550
2595 BM The Hague
The Netherlands

www.vereniginginnovatievegenesmiddelen.nl

Dutch Association Innovative Medicines

The Dutch Association Innovative Medicines is a branch organization that represents more than 40 innovative (bio)pharmaceutical companies in the Netherlands that are focused on research and development of new medicines.

Innovative medicines and vaccines are essential for our health, economy and society. Therefore, the association strives for optimal conditions for positioning the Dutch innovative medicines sector as a crucial player for the sustainable development of and optimal access to new medicines and vaccines.

We aspire to lead the Netherlands within Europe in:

- Broad and rapid access;
- Better and longer lives;
- Innovation.

We do this in an open dialogue and co-creation with our stakeholders, both professionals and the general public.

We are stronger together!



FAST

Centre for Future Affordable Sustainable Therapy development



Clémence Ross

Vice President

info@fast.nl

FAST is a centre of expertise and collaboration, commissioned by the Dutch government. The centre is initiated to foster faster, smarter, and sustainable development, production and access of new therapies for patients. It bundles and unlocks expertise and stimulates connectivity in the ecosystem. Opportunities and hurdles are identified, prioritized and subsequently tackled in an integrated manner, for example in use cases, experiments and pilot studies.



Benien Vingerhoed

Managing Director

+316 3450 1714

[benien.vingerhoed@](mailto:benien.vingerhoed@fast.nl)

[fast.nl](mailto:benien.vingerhoed@fast.nl)

FAST connects stakeholders who are actively involved in the process of innovative therapy development, such as researchers, patients, entrepreneurs, science parks and regulatory authorities.



FAST

Laan van

Nieuw Oost-Indië 334

2593 CE The Hague

The Netherlands

www.fast.nl



Health~Holland



Carmen van Vilsteren

Chair

[vilsteren@](mailto:vilsteren@health-holland.com)

health-holland.com

Top Sector Life Sciences & Health (Health~Holland) works together with public and private parties to promote the economic opportunities of the societal theme Health & Care of the Dutch cabinet's Mission-driven Top Sectors and Innovation Policy. The coalition does this on the basis of the five Health & Care missions, formulated by the Ministry of Health, Welfare and Sport.



Hans Schikan

Top Team Member

+31 6 1432 6768

hans.schikan@gmail.com

The central mission is as follows: By 2040, all Dutch citizens will live at least five years longer in good health, while the health inequalities between the lowest and highest socioeconomic groups will have decreased by 30%. There are four underlying missions that contribute to this central mission through changes to lifestyle and living environment, offering more care in the right place and better perspectives for people with chronic diseases, lifelong disabilities and dementia. With this approach, the Netherlands seeks to effectively tackle major societal challenges. Industry can optimally respond to the economic opportunities that these challenges bring.



Laura Duran

International Relations

Manager

+31 6 2853 2689

duran@health-holland.com



Health~Holland

Wilhelmina van Pruisenweg 104

2595 AN The Hague

The Netherlands

www.health-holland.com

[Meet the Health~Holland team](#)



HollandBIO



Annemiek Verkamman

Managing Director
+31 6 2153 1104

annemiek.verkamman@hollandbio.nl

HollandBIO is the Dutch biotechnology industry association. HollandBIO aims for a maximal contribution of life sciences and biotech to a healthy and sustainable society. Under the motto “challenge the status quo”, HollandBIO concentrates its efforts on removing the obstacles that get in the way of our frontrunners. We are very proud to represent over 270 member companies: startups, SMEs and multinational companies that work on new therapies, vaccines, diagnostics, food, cultivated meat or the biobased economy.



HollandBIO

Laan van Nieuw
Oost-Indië 131
2593 BM The Hague
The Netherlands
www.hollandbio.nl



Eline van Beest

CEO

+31 6 4224 1411

eline@hybridizetx.com

**Hybridize
Therapeutics**

De Limes 7

2342 DH Oegstgeest

The Netherlands

[www.hybridize
therapeutics.com](http://www.hybridizetherapeutics.com)

Hybridize Therapeutics

We want to give patients that suffer from untreated kidney diseases a perspective to be treated. We bring unique expertise and perspectives together to develop RNA-based therapies with this purpose.

RNA therapeutics for the kidney

Our mission is to unlock the kidney as an organ. We focus on kidney delivery and work with a discovery engine to become the RNA expert for kidney diseases. While oligonucleotides naturally accumulate in the kidney, Hybridize aims to improve kidney uptake and enable cell-specific targeting of its RNA therapies.

Validated technology (100mIn deal)

Hybridize's initial program is an innovative RNA-based therapy that targets the BK-virus and was out licensed to AiCuris with a total deal value of €100mIn. BK-virus is a highly prevalent renal virus that can cause major clinical issues for immunocompromised kidney transplant patients.

Strong team and network

The team is built by experienced people in the field of RNA therapeutics and entrepreneurship. Hybridize is a spin-off from the Leiden University Medical Center (LUMC). The LUMC has played a pioneering role in both nephrology and RNA-based medicine since 1943.

For more information, please visit
www.hybridizetherapeutics.com



Intravacc



Jan Groen

CEO & Chairman

+31 6 1524 7321

Jan.Groen@Intravacc.nl

Intravacc is an established independent CDMO with years of experience in developing and optimizing vaccines for infectious diseases and therapeutic vaccines, which has transferred its technology worldwide for vaccines against polio, measles, diphtheria, Hib, and influenza. Around 30% of childhood disease vaccines are based on Intravacc's technology and knowhow.

Intravacc offers a wide range of expertise for independent vaccine development, from concept to Phase I/II clinical studies, for customers around the world.

Intravacc continues to capitalize on the critical global trends in healthcare: the ever-growing need for prevention and intervention for infectious diseases and cancer. Our innovative vaccine platforms and vaccine contract development and manufacturing capabilities are well positioned to address the unmet needs in the vaccine and immune therapy market which is currently estimated at \$37 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% to \$55 billion by 2027.

The company's head office is located on the Utrecht Science Park location Bilthoven, The Netherlands, and has state-of-the-art laboratories and GMP production facilities. Intravacc is a limited liability company incorporated under Dutch law. Intravacc is a state holding company since 1 January 2021, under the Ministry of Health, Welfare and Sports (VWS).



Intravacc

Antonie van Leeuwen-

hoeklaan 9

3721 MA Bilthoven

The Netherlands

www.Intravacc.nl

Janssen Biologics



Manuella Wilts
Acting General Manager
+31 6 1107 5912
Mwilts@its.jnj.com

At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, researching and developing treatments and preventive solutions for some of the most devastating diseases and complex medical challenges of our times.

We focus on six therapeutic areas where we can make the biggest difference: Immunology; Infectious Diseases & Vaccines, Neuroscience; Oncology; Cardiovascular, Metabolism & Retina; and Pulmonary Hypertension.

At Janssen Biologics, we use our biotechnical experience, expertise, and technology to manufacture, test and deliver complex biological medicines and vaccines to patients around the globe. All our innovative treatments start their production process with the aid of living cells and are manufactured with the highest safety and quality standards.

In The Netherlands, Janssen has more than 2500 employees in three different entities: Janssen Biologics for high-tech production, Janssen-Cilag as the commercial entity, and Janssen Vaccines & Prevention as Research & Development focused entity in the domain of infectious diseases. Janssen ranks at the third position in R&D investing, private companies in The Netherlands.



Janssen Biologics
Einsteinweg 101
2333 CB Leiden
The Netherlands
www.janssen.com



Janssen-Cilag



Michel van Agthoven

Head Janssen/J&J Campus
The Netherlands and
Director External Affairs
Janssen The Netherlands
+31 6 5150 2084
mvagthov@its.jnj.com

At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, researching and developing treatments and preventive solutions for some of the most devastating diseases and complex medical challenges of our times.

We focus on six therapeutic areas where we can make the biggest difference: Immunology; Infectious Diseases & Vaccines, Neuroscience; Oncology; Cardiovascular, Metabolism & Retina; and Pulmonary Hypertension.



Erik Holl

Managing Director Janssen
The Netherlands
+31 6 5397 7929
eholl@its.jnj.com

At Janssen Biologics, we use our biotechnical experience, expertise, and technology to manufacture, test and deliver complex biological medicines and vaccines to patients around the globe. All our innovative treatments start their production process with the aid of living cells and are manufactured with the highest safety and quality standards.

In The Netherlands, Janssen has more than 2500 employees in three different entities: Janssen Biologics for high-tech production, Janssen-Cilag as the commercial entity, and Janssen Vaccines & Prevention as Research & Development focused entity in the domain of infectious diseases. Janssen ranks at the third position in R&D investing, private companies in The Netherlands.



Janssen-Cilag

Graaf Engelbertlaan 75
4837 DS Breda
The Netherlands
www.janssen.com



Kadans Science Partner



Johan van Gerven
Director Development
+31 6 5358 2847
j.gerven@kadans.com

Kadans Science Partner's mission is to build and support innovative ecosystems. With industry-leading intelligence, -knowledge and experience Kadans offers state-of-the-art specialist accommodation and access to an ecosystem of industry-leading businesses, optimising our tenants' success and stimulate innovation together.

Kadans focuses on investing in (developing, investing, building, financing and buying), leasing and managing Technical Laboratory & office facilities throughout Europe. From laboratories and clean rooms to research facilities and climate-controlled spaces, we design and build inspiring buildings inhabited by inspiring people.

Through our in-house teams, Kadans stays involved with all tenants and can quickly respond to an organisation's changing accommodation needs. Tenants benefit from our flexible commercial structures which allow for financial resources to be saved which can be used for the core business, thus stimulating innovation.

Kadans believes in the power of collaboration, and carefully selects its tenants and external partners to create opportunities, share knowledge and resources, and work together to achieve shared goals. We take a proactive approach to building this innovation ecosystem.



Kadans Science Partner

Rijksweg 5
5076 PB Haaren
The Netherlands
www.kadans.com



Ida Haisma

Director Leiden Bio
Science Park Foundation
+31 6 1203 7710
ihaisma@lbsp.nl

Leiden Bio Science Park

The Leiden Bio Science Park (LBSP) has acquired over the past 39 years, a strong, global position. With a.o. innovative companies, researchers and start-ups on the premises, LBSP Foundation is committed to develop the future. Established almost 40 years ago, we have evolved into the Netherlands' largest LSH cluster, connecting talent, researchers and entrepreneurs to work on achieving healthy lives for everyone. Within the district you will find companies, educational and research institutions, unique facilities and valuable collaboration on the entire drug development chain.

LBSP is a hub for progress. Our team focuses on the positioning of the district and its community of more than 21,000 innovators and 22.500 students. With access to Knowledge, Innovation, Human Capital, Capital and Market, we try to streamline a most efficient learning and production process between and within these learning communities. Do not hesitate to visit our [website](#) and/or subscribe to our newsletter for the latest news or updates on our high-quality programmes.



**Leiden Bio Science Park
Foundation**

Galileiweg 8
2333 BD Leiden
The Netherlands
leidenbiosciencepark.nl



Universiteit
Leiden

Leiden University



Hubertus Irth

Scientific Director, Leiden
Academic Centre for Drug
Research

+31 6 4165 4198

h.irth@lacdr.leidenuniv.nl

Founded in 1575, Leiden University is pioneering research and teaching based on a wide diversity of academic disciplines. We firmly believe that working and studying in an international community generates new insights, inspiring contacts and more creative research and teaching. Life Sciences constitutes one of the five key research areas of Leiden University, with a special focus on drug discovery and development. There are many complex links in the chain that provides patients with new drugs: from fundamental science, to clinical tests, to production. The entire chain can be found in Leiden.

Researchers from the Leiden Academic Centre for Drug Research, the Leiden Institute for Chemical Research and the Leiden Institute of Biology collaborate to make the hunt for new drugs as efficient as possible. Researchers from the Leiden Academic Centre for Drug Research, the Leiden Institute for Chemical Research and the Leiden Institute of Biology work closely together to discover new targets for drugs and to develop molecules that act on them. LBSP is just a stone's throw away from the buildings of Leiden University and the LUMC. On this site of over 110 hectares, more than 200 businesses and institutes focus on numerous different aspects of drug development.

Leiden University

Rapenburg 70
2311 EZ Leiden
The Netherlands

Leiden Academic Centre for Drug Research

Einsteinweg 55
2333 CC Leiden
The Netherlands
www.leidenuniv.nl



Peter Ketelaar
Managing Director
+31 6 5333 5810
peter@lifecooperative.nl

Life Cooperative

Life Cooperative has the ambition to boost the life science & health innovation in Northern Netherlands, to further strengthen and grow the ecosystem, with the objective to impact health(care) and healthy aging. With our cooperative approach we want to accomplish this ambition together with local governments and knowledge institutes.

The focus will be on:

- Develop and execute an effective human capital strategy with local knowledge institutes
- Building shared laboratory & manufacturing facilities
- Create easy access to funding for our members.

Furthermore, we organize collective training, combined purchasing of laboratory equipment and materials, and shared visits to international fairs and congresses.

The LIFE Cooperative represents 50 startup and SMEs in the Life Sciences & Health sector in the Northern Netherlands. Together we are making the difference.

Life Cooperative
L.J. Zielstraweg 2
9713 GX Groningen
The Netherlands
www.lifecooperative.nl

Loyens & Loeff



Kim Lucassen
Attorney-at-law (partner)
+31 6 5342 6454
kim.lucassen@loyensloeff.com

As a leading firm, Loyens & Loeff is the logical choice for a legal and tax partner if you do business in or from the Netherlands, Belgium, Luxembourg and Switzerland, our home markets. You can count on personal advice from any of our 1000 advisers based in one of our offices in the Benelux and Switzerland or in key financial centres around the world. Thanks to our full-service practice, specific sector experience and thorough understanding of the market, our advisers comprehend exactly what you need.

LSH Team



Hamza Zourakhti
Attorney-at-law (senior associate)
+31 6 1090 1502
hamza.zourakhti@loyensloeff.com

Rapid transformation in the Life Sciences & Healthcare industry requires organisations to strike a balance between market potential, policy compliance and patient demands with continued innovation.

We are all affected by this sector, and it falls under heavy social and political scrutiny. Regulation of competition in the sector has also made it increasingly dynamic and challenging. As the demand for life sciences and healthcare services is ever-growing, so too are the strains and scrutiny placed on its decision makers.

With the largest Life Sciences & Healthcare Team in the Dutch market, we can relate to our clients and deliver top tier services during all the stages of business lifecycle.

Loyens & Loeff
Parnassusweg 300
1081 LC Amsterdam
The Netherlands
www.loyensloeff.com



MSD



Leonardo Mallmann

AVP, Managing Director

+31 6 4348 6123

leonardo.mallmann@merck.com



Frank Mattijssen

Executive Director

Finance

+31 6 2246 0245

frank_mattijssen@merck.com

MSD, part of the international company Merck & Co, offers innovative treatments to improve both human and animal health. The company has been at the heart of Dutch society for almost 100 years: today, MSD employs over 5,000 people in The Netherlands, who deliver on our purpose to save and improve lives with heart, soul and pride.

As an important and valued employer, MSD's innovation and production power make it a major economic player at a local, national and international level. From its four Dutch sites, MSD develops, researches, tests, manufactures, and packages medicines and vaccines – all from the Netherlands. And we export our products to over 140 countries worldwide. In Haarlem, we manufacture and package vaccines and medicines. This is also where we built our sustainable cold store and innovative laboratory. Together, our locations in Boxmeer and De Bilt are MSD's largest R&D facility for animal health solutions worldwide. In Oss we focus on biotechnology: a field in which we were one of the pioneers 25 years ago. This site contributed substantially to the early development of immunotherapy, and it still plays an important role in the production of this innovative cancer treatment.



MSD

Waarderweg 39

2031 BN Haarlem

The Netherlands

<https://msd.nl>



Frank den Brok
Alderman for Finance and
Economy
+31 6 4681 4724
f.den.brok@oss.nl

Municipality Oss

The municipality of Oss is a city in the Netherlands. As a city, Oss has a strong track record in manufacturing in Life Sciences. Life Science fits perfectly with our future, which is why the municipality will be happy to support any company who wants to start a business. We will do that with our greatest asset: our people. The people of Oss are known for their no-nonsense attitude, their mantra of work hard and work smart. In Oss, business people create partnerships in business, but do so with education, research, and government parties as well. As a result, an exceptional network of industry, research, academic and professional training has been created in Oss and the region, ready to support your business. They have life sciences companies such as MSD, Organon, and Aspen and also Pivot Park, a life sciences campus.



Municipality Oss
Raadhuislaan 2
5340 BA Oss
The Netherlands
www.oss.nl



Maurits Geerlings

Chief Executive Officer

+31 6 2953 3788

mgeerlings@nanocelltx.com

NanoCell Therapeutics

NanoCell Therapeutics is a trans-Atlantic company developing a New Biological Entity-based targeted gene delivery platform, with the vision to make cell engineered therapies truly affordable, scalable, and widely accessible for the general patient population.

Our cell-directed nanoparticle technology is able to deliver DNA plasmids without viral vectors to specific cells of interest, such as T cells, upon intravenous administration. Because DNA stably integrates into the target cell's genome, our therapies are designed to provide durable efficacy, thereby overcoming limitations of RNA-based therapies. Our new class of medicines has the potential to transform the fields of CAR- and TCR therapy, as well as somatic gene therapy.

Our cell-directed nanoparticles can also be directed to monocytes, NK cells, B cells, monocytes, hepatocytes, endothelial cells, and many other cell types, which broadens the spectrum of applicable clinical indications beyond oncology, to include autoimmune/inflammatory, infectious, cardiovascular, protein/enzyme deficiency, and other diseases.

NanoCell Therapeutics

Padualaan 8

3584 CH Utrecht

The Netherlands

www.nanocelltx.com



Neolook Solutions



Marco D'Agata

CEO

+31 6 3949 0555

[marco.dagata@](mailto:marco.dagata@neolooksolutions.com)

neolooksolutions.com

Neolook Solutions

Neolook is a beautiful spin-out of Philips with a global business case. Though a young company, our value proposition is acknowledged and valued by leading hospitals in The Netherlands and Europe.

We develop and commercialize so called video augmented services for babies and children in intensive care. These are:

- Involving parents, siblings, and relatives to increase family bonds and to prevent traumatic fallout (Neolook Family).
- Supporting scientific research, drive continuous innovation by longform, high resolution data capture which is instant ready for data science and AI. Including a stack of key clinical AIs for diagnostic and therapeutic purposes (Neolook Academic).
- Serve nurses and doctors in day-to-day challenging practice with line-of-sight solutions, remote consultations, and diagnostics (Neolook Professional).



Neolook Solutions

Padualaan 8

3584 CH Utrecht

The Netherlands

www.neolooksolutions.com



Hilde van der Meer
Commissioner
+31 6 5122 7465
hilde.vandermeer@rvo.nl



Sandra de Wild-Chardonnes
Head of Strategic Projects
& Business Climate
+31 6 5074 8054
sandra.dewild@rvo.nl



**Netherlands Foreign
Investment Agency**
Prinses Beatrixlaan 2
2595 AL The Hague
The Netherlands
www.investinholland.com

Netherlands Foreign Investment Agency

Invest in Holland: Connect with us to advance health and care for all

Invest in Holland is the national network of the Netherlands Foreign Investment Agency (NFIA), an operational unit of the Dutch Ministry of Economic Affairs and Climate Policy, and our regional and local partners. Together, we advise foreign companies with ambitions to solve global challenges through expansion in Europe. We can guide you on your road to business expansion in the Netherlands, providing relevant information and connecting you to the right resources and partners. With our expert team of life sciences specialists and global network of foreign offices, we know how to connect the international industry with business opportunities in the Netherlands. Our flourishing international life sciences ecosystem offers specialized research clusters and powerful public-private partnerships – enabling you to develop, test and market your innovations. Let's start the conversation about advancing health and care with the Netherlands.

Interested? Contact lsh@investinholland.com

Latest developments in the LSH sector in the Netherlands:

- [Viz.ai Expands to the Netherlands with a Focus on Life-Saving Diagnostics >](#)
- [Organon Opens Experience Center in the Netherlands on International Women's Day >](#)
- [NanoString Technologies Establishes EMEA Headquarters in the Netherlands >](#)



Nostics



Vincent Laban

Co-founder & CEO

+31 6 5055 0886

vincent.laban@nostics.com

Nostics' novel diagnostics platform technology powers its mission to provide data-driven, accessible testing for all. Combining Nobel prize winning science, advanced nanotechnology & AI, Nostics provides easy-to-use, handheld, and cloud-based solutions, able to detect and identify pathogens from patient samples in only 15 min.

Everyone deserves to be in good health and get the right treatment when they are sick. The rapid increase of antimicrobial resistance and the spread of infectious diseases is endangering global healthcare, as treatments become ineffective and unaffordable.



Eva Rennen

Co-founder & COO

+31 6 2878 5479

eva.rennen@nostics.com

At Nostics, we believe that no antimicrobial treatment should start without an accurate diagnosis, and that every healthcare professional should have access to data-driven diagnostics, without the need for a lab. Ensuring we can prescribe the correct, narrow-spectrum antimicrobials, prevents over-use, misuse, and patient burden. Affordable, battery operated, dust, temperature, and shock resistant, the platform is made to be used even in the most rural locations.

The company was founded in 2020, employs 24 people, and is based in the Netherlands and the US. Nostics is in the process of obtaining FDA approval and CE certification for their first product.



Nostics

Pietersbergweg 199

1105 BM Amsterdam

The Netherlands

www.nostics.com



Novartis



Jan Güse

Head Public Affairs

+31 6 5354 4008

jan.guse@novartis.com

Novartis is a pharmaceutical company committed to making a meaningful contribution to healthcare. By leveraging science-based innovations, we strive to achieve better treatment outcomes for patients around the world. In our search for new medicines, we are consistently among the world's top companies, investing in research and development. Worldwide, Novartis' products reach nearly 1 billion people.

We have a clear focus on five core therapeutic areas (cardiovascular, immunology, neuroscience, solid tumors, and hematology), with multiple significant in-market and pipeline assets in each of these areas, that address high disease burden and have substantial growth potential. In addition to two established technology platforms (chemistry and biotherapeutics), three emerging platforms (gene & cell therapy, radioligand therapy, and xRNA) are being prioritized for continued investment into new R&D capabilities and manufacturing scale. About 110,000 people with 149 nationalities work at Novartis worldwide.

Novartis Netherlands employs around 250 people. Our strategy is to deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. We dedicate ourselves every day with enthusiasm and passion to our mission: to reimagine medicine to improve and extend people's lives.



Novartis Netherlands

Haaksbergweg 16

1101 BX Amsterdam

The Netherlands

www.novartis.com/nl-nl



Weite Oldenziel

CEO

+31 6 4131 0508

oldenziel@ofichem.com

Ofichem Group

The Ofichem group has a pivotal role in the production of safe and effective human and veterinary medicines. The Ofichem group is a fully integrated global pharmaceutical company, with a multitude of individual, yet synergetic activities in the field of active pharmaceutical ingredients (APIs; i.e. drug substance) and of finished dosage forms (i.e. drug product). The synergy between the different business units makes the Ofichem Group a knowledgeable and reliable partner.

The activities in drug substance:

- CRO and C(D)MO activities of new chemical entities and revival of generic APIs
- Commercial production of own portfolio of APIs, including isolation of plant based substances
- Repackaging and distribution of APIs of third-party producers
- Additional services as analytical work for third parties and third-party supplier qualification (audits in South East Asia)

The activities regarding drug products are:

- CMO activity for clinical trial material
- CMO activity and own portfolio of MAH in generic drug products.



Ofichem Group

Heembadweg 5

9561 CZ Ter Apel

The Netherlands

www.ofichem.com

The Ofichem group is a family owned business, established in the mid-70s. We maintain a global network, and it is our ambition to serve as a strategic partner for clients, with a professional demeanor and competitive pricing as our key selling points.



Organon



Wenny Raaijmakers

Site Lead Organon Oss
+31 6 3039 4316
wenny.raaymakers@organon.com



Petra Willems

Managing Director Organon
Benelux
+31 6 2049 5040
petra.willems@organon.com

Organon is a global healthcare company formed through a spinoff from Merck & Co., Inc. (known as MSD outside of the U.S. and Canada) with a mission to deliver impactful medicines and solutions for a healthier every day. We build upon our strong foundation of more than 60 medicines and other products across a range of areas including reproductive health, heart disease, dermatology, allergies, and asthma.

We bring these important therapies around the world, with an international footprint that serves people in more than 140 markets. We believe the diversity of our business provides a sustainable engine of growth so we can continue to invest in and advance new medicines and treatments for women that are so urgently needed.

We are here for her health.



Organon Oss

Kloosterstraat 6
5349 AB Oss
The Netherlands

Organon Amsterdam

Fred Roeskestraat 115
1076 EE Amsterdam
The Netherlands
www.organon.com



Orgonex



Jasper van Berkel
Chief Operations Officer
+31 6 2118 5319
J.vanberkel@orgonex.com

Orgonex is a pioneering Dutch biotechnology company, headquartered in Utrecht, that was founded in 2023 as a spin-off of Utrecht University.

Orgonex focuses on the development, production and commercialization of a spinning bioreactor for organoid culture, the RPMotion. The RPMotion is based on breakthrough research from the internationally highly rated Faculty of Veterinary Medicine at Utrecht University. We are committed to creating groundbreaking hardware solutions in the field of organoid technology by reducing the effort of the current culturing methods in a sustainable way and continue to work on innovative solutions in this area together with our strategic partners.

Organoids are best described as mini-organs, 3D structures of cells made up of different cell types that are organised in the same way as a real organ. An organoid has the same basic properties as an organ and in principle, it is possible to make an organoid from all organs and species. That is why the potential of this technology is so enormous. Organoids have been established from intestine, liver, heart, lung, brain, eyes, skin, uterus, placenta and even more. Organoids from a specific patient have the same properties as the patient's organ, including any diseases and abnormalities. This makes it possible to target research very specifically and create an important role for organoids in drug discovery. In addition to specific drug development, organoids open doors to personalised medicine, where we can test the effectiveness before a drug is prescribed to a patient, so the right drug choice can be made, or the correct dosage can be determined.



Orgonex
Padualaan 8
3584 CH Utrecht
The Netherlands
www.orgonex.com



Jeroen Elassaiss - Schaap

CEO / Founder

+31 6 2311 8438

jeroen@pd-value.com

PD-value

PD-value is a translational pharmacometrics service provider founded in 2014 by Jeroen Elassaiss-Schaap, a recognized senior scientist with more than 20 years of experience in the pharmaceutical industry. Since 2016, PD-value has a sister company, Gedmore, specializing in the automation of pharmacometric modeling for discovery. Next to PK-PD, PD-value includes mathematical modeling and systems biology simulation services in its portfolio. PD-value acquired SysBioSim, a dedicated systems biology company, as of January 2021 and integrated the expertise in systems biology and network modeling.

The integrated services include:

- PK-PD services
- experiment & study design support
- early clinical strategy consultancy services
- performing predictive analysis with signaling and metabolic pathways models
- development of specifically designed models to answer research questions based on existing literature and proprietary client data
- analysis on the efficacy, efficiency, dosage, and adverse events of drug candidates

The services and expertise of PD-value enhanced with systems biology services present value to the clients by improving design of R&D programs, animal and clinical studies, and accelerate decision making. PD-value is located in the Utrecht Science Park and has a growing team of scientists with diverse backgrounds.



PD-value

Yalelaan 1

3854 CL Utrecht

The Netherlands

<https://pd-value.com>



Ypke van Oosterhout

CEO

+31 6 1101 7611

[y.vanoosterhout@](mailto:y.vanoosterhout@philikos.com)

philikos.com

Philikos

Philikos develops innovative therapeutics for systemic sclerosis (SSc), a rare debilitating and life-threatening autoimmune disease characterized by inflammation and fibrosis. Currently, there are no disease modifying agents available.

Philikos' unique approach, T-Guard, is a combination of two toxin-conjugated antibodies that rebalance the immune system by transient depletion of activated autoreactive T cells and NK cells.

Philikos is based on the technology and solid Phase 3 data package of Xenikos – that developed T-Guard for acute graft-versus-host disease. For SSc, Philikos demonstrated in vitro proof-of-concept and is ready to initiate a Phase 1/2b trial. Currently the company is looking for Seed-financing for completing the clinical proof-of-concept.

Philikos was founded in 2023 in Nijmegen and has an experienced management team complemented by top-notch advisors and partners. Strategic partners include the Radboudumc SSc expertise center and Dutch Arthritis Society.

Philikos

Javastraat 122

6524 ML Nijmegen

The Netherlands

www.philikos.com

pivotpark



Brigitte Drees

CEO Pivot Park & PPSC

+31 6 2161 3066

[brigitte.drees@](mailto:brigitte.drees@pivotpark.com)

pivotpark.com



Mirjam van den Bosch

Chief Business Officer PPSC

+31 6 8240 1996

[Mirjam.vandenbosch@](mailto:Mirjam.vandenbosch@ppscreeningcentre.com)

ppscreeningcentre.com



Pivot Park / PPSC

Kloosterstraat 9

5349 AB Oss

The Netherlands

www.pivotpark.com

www.ppscreeningcentre.com

Pivot Park / PPSC

Pivot Park

We have a clear mission: if we invest in building a world-class biopharmaceutical R&D infrastructure it will create the perfect conditions for new, young and established companies to grow. This will support the development of a dynamic, pharma-based knowledge community. Together we will improve global health.

Pivot Park is located in entrepreneurial Oss, the spiritual home of the Dutch pharmaceutical industry. An ideal place to attract talent, spark new ideas and support growth; whilst simultaneously offering an unmatched work-life balance. Supporting 1,000 highly qualified people at over 60 companies, we make sure they have what they need to succeed.

Pivot Park Screening Centre (PPSC)

Your optimal partner in early drug discovery.

We provide drug discovery services in the fields of biochemical and cellular assay development, lab automation, ultra- High-Throughput Screening (uHTS, usually in 1536-well format) and hit-to-lead biological profiling, in order to find novel leads for drug development.

All major read-out modalities including Mass Spectrometry are available in-house ensuring rapid generation of high-quality hits.

You can either bring your own compound library or use our 300K IP-free druglike compound library. Our fully automated robot system can handle over 1 mln. compounds per screen.

POONAWALLA SCIENCE PARK BV

UTRECHT
SCIENCE
PARK
BILTHOVEN



Jozef De Clercq

CEO

+31 6 4605 8021

[jef.de.clercq@](mailto:jef.de.clercq@poonawallasciencepark.nl)

poonawallasciencepark.nl



Jorrit van Hoorn

Director Corporate

Development

+31 6 2060 3753

jorrit.van.hoorn@bbio.nl



Poonawalla Science Park

Antonie van Leeuwenhoek-
laan 9-13

3721 MA Bilthoven

The Netherlands

poonawallasciencepark.nl

Poonawalla Science Park

Poonawalla Science Park is owner of USPB (Utrecht Science Park Bilthoven), a scientific campus of 22.5 hectares in Utrecht.

PSP is renting out the +/- 60 buildings on the terrain and is also providing an extensive package of facility services to the tenants.

In the coming future (2 years), the present main tenant RIVM (Dutch Ministry of Health) will move to a new building/location at USPU across the road and hence freeing 65,000 sqm of office and lab space at USPB.

PSP is now preparing a development vision for the campus for renovating and creating new office/lab space on the campus after the leave of RIVM. The intended future new tenants should be active in the biotech or pharma sector preferably in the field of vaccine development and/or manufacturing.



Protinhi Therapeutics



Bernd van Buuren

Co-founder and CEO

+31 6 4810 5658

b.vanbuuren@protinhi.com

Protinhi Therapeutics is a Dutch preclinical-stage biopharmaceutical company aiming to create a world where effective treatments are available against (re) emerging viral infections. We focus on antiviral drugs against dengue/broad-spectrum flaviviruses and have additional programs on broad-spectrum coronaviruses.



Ashley Shih

Business Developer

+31 6 4475 5303

a.shih@protinhi.com

Our proprietary technology platform employs peptidomimetic compounds to inhibit proteases essential to virus replication. Protinhi has demonstrated the high efficacy of our preclinical candidates in reducing viremia in vivo proof of concept studies against dengue (therapeutic and prophylactic). The unique PKPD-properties of our drug candidate further enables us to develop a novel, easy-to-administer and long-acting antiviral drug which allows single-dose regimen per therapeutic/prophylactic treatment.

Advancing the development of our drug candidates to novel drugs will help us fulfil our mission to help patients overcoming viral infectious diseases and enjoy a high quality of life. We aim to prepare global society to prevent future epidemics/pandemics and the subsequent huge burdens, thus contributing to pandemic preparedness.



Protinhi Therapeutics

Transistorweg 5

6534 AT Nijmegen

The Netherlands

www.protinhi.com

Radboudumc

Radboud university medical center



Alexander Nicastia

Head of Business

Development

+31 6 2737 8737

[alexander.nicastia@
radboudumc.nl](mailto:alexander.nicastia@radboudumc.nl)

Radboud university medical center is a university medical center for patient care, research, and education, located in Nijmegen.

Radboud university medical center strives to be at the forefront of shaping the health and healthcare of the future. This is reflected in our mission: “to have a significant impact on health (care)”.

It demands that we innovate and reinvigorate through collaboration within our networks and with a focus on the individual person.

We mainly concentrate on prevention, meaningful and prudent healthcare, sustainability, artificial intelligence and data-driven systems, the molecular mechanisms of diseases and new treatments, and training the professionals of tomorrow.



Dennis Lammers

Deputy Director

Radboudumc Holding

+31 6 4348 9414

[dennis.lammers@
radboudumc.nl](mailto:dennis.lammers@radboudumc.nl)

Radboud university medical center

Geert Grooteplein 10

6525 GA Nijmegen

The Netherlands

www.radboudumc.nl



rijksmuseum
boerhaave



Amito Haarhuis

Director

+31 6 5265 3235

[directie@](mailto:directie@rijksmuseumboerhaave.nl)

rijksmuseumboerhaave.nl



Carmen Cabo

Head of Development &
Partnerships

+31 6 8232 2235

[carmencabo@](mailto:carmencabo@rijksmuseumboerhaave.nl)

rijksmuseumboerhaave.nl



Rijksmuseum Boerhaave

Langs St. Agnietenstraat 10

2312 WC Leiden

The Netherlands

www.rijksmuseumboerhaave.nl

Rijksmuseum Boerhaave

At National Museum Boerhaave you get to discover more about the most important inventions from the history of science in the Netherlands. The collections reflect five centuries of the history of science. It is also evident in our top collection, such as the microscopes of Antoni van Leeuwenhoek, the first pendulum clock by Christiaan Huygens, the oldest heliocentric planetarium in the world, anatomical preparations and objects relating to Dutch Nobel Prize laureates.

The museum offers young and old a peek into the fascinating world of science. The world-famous collection and the newly designed interior show what science is all about: curiosity, courage, creativity and perseverance.

In a world of rapidly accelerating scientific and technological change, we regard it as our task to involve people in this process and show them where these developments are coming from. We believe it will lead to a greater understanding of science and the remarkable achievements of research and innovation.

We are taking the initiative to develop the prime hotspot for biotechnology in the Netherlands. The Life Science & Health Studio is designed to become a space where visitors can become fascinated by biotechnology and get to understand the world of life sciences and innovative medicine.



Andrew N. Plank
General Manager
+31 6 2241 3863
andrew.plank@roche.com



Jacco Lieste
Country Medical Director
+31 6 5150 0647
jacco.lieste@roche.com

Roche Nederland

Throughout our 125-year history, Roche has grown into one of the world's largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas. Our commitment to our people, partners, stakeholders and, most importantly, our patients remain as strong as it was on the first day of our journey.

We focus on finding new medicines and diagnostics and establishing data-based insights that evolve the practice of medicine and help patients live longer, better lives.

Healthcare is undergoing tremendous changes but our vision is clear. We are doing now what patients need next. Being a family-owned company allows us to focus on long-lasting investments, take greater risks and explore innovative new ways to improve people's health around the world.

We've partnered with many forward-thinking, entrepreneurial and groundbreaking organizations that have one thing in common - the belief that cutting-edge science and technology can and will improve human health. We work on personalized health from both perspectives: diagnostics and medicine. To achieve our goal: "the right treatment for the right patient at the right time".

Roche Nederland

Beneluxlaan 2a
3446 GR Woerden
The Netherlands
www.roche.nl



Rotterdam Square



Ellen Smit

Managing Director

+31 6 5717 5864

[ellen.smit@](mailto:ellen.smit@rotterdamsquare.nl)

rotterdamsquare.nl

Rotterdam Square is the organization that connects the Life Sciences & Health ecosystem in the Rotterdam region. Located in the vibrant heart of Rotterdam, and part of the new Erasmus Medical Center Campus, Rotterdam Square is a central location for creating partnerships and collaboration with Erasmus MC, Erasmus University and the Delft University of Technology.

Connecting international Life Sciences & Health collaboration

Our goal is to bring together experts in healthcare, science and technology, from academia and industry, to accelerate innovations in Health and Tech and create healthcare solutions for the future.



Sharon Mullen

Senior Account Manager

+31 6 1116 0625

[sharon.mullen@](mailto:sharon.mullen@rotterdamsquare.nl)

rotterdamsquare.nl

We connect researchers and companies on a regional, national and international level, organize networking events and support companies in creating promising partnerships, drawing upon our extensive knowledge of the Life Sciences & Health sector.

Working in collaboration with partners such as the Municipality of Rotterdam, Invest in Holland and Health~Holland, Rotterdam Square helps your company to successfully integrate in and connect to the Rotterdam ecosystem and be part of the Dutch connected Life Sciences & Health metropolis, to establish new healthcare innovations that benefit our patients.



Rotterdam Square

Dr. Molewaterplein 40

3015 GD Rotterdam

The Netherlands

www.rotterdamsquare.nl



Sanofi



Denis Peeters

Country Lead the
Netherlands

+31 6 1067 2798

Denis.Peeters@sanofi.com

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine, turning the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.



Mignon van der Westerlaken

Head Public Affairs &
Communications

+31 6 104 89 212

Mignon.vanderWesterlaken@sanofi.com

In the Netherlands, we host about 650 colleagues in our Amsterdam offices, in different roles: serving Dutch patients and healthcare professionals, being involved in global functions or actively develop the treatments of the future via our Research & Development activities.



Sanofi

Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands
www.sanofi.com



Sophia Shanko
CEO & Founder
+31 6 2484 5112
[e.s.shanko@
shanxmedtech.nl](mailto:e.s.shanko@shanxmedtech.nl)

ShanX Medtech

The lack of rapid, in-house testing of antibiotic efficiency urges physicians to overprescribe drugs for the treatment of bacterial infections empirically thereby compromising drug efficacy and overall patient outcome.

We have developed a novel sample-in, result-out hardware system that quickly informs physicians of the optimal antibiotic therapy tailored to each patient's needs and at the point of care.

Though antibiotics are our first tested drugs, the platform system can be used for other anti-infectives and in general for other (old and/or newly developed) medicines.

Our innovation is a must to enable fast, evidence-based and personalized drug administration, which is crucial to avoid medication overprescription.

ShanX Medtech

Het Eeuwsel 57
5612 AS Eindhoven
The Netherlands
www.shanxmedtech.com



Bert Trentelman
Founder / Director
+31 6 4608 1843
bert@src-search.com



Tom Hunter
Senior Consultant
+31 6 4841 4588
tom@src-search.com

SRC-Search

SRC-Search was established in 2012 to offer an unrivalled recruitment experience within the life science, diagnostic, analytical and medical industries across the globe. Our clients range from start-ups to small-medium enterprises up to global market-leaders looking to fill positions ranging from entry-level to the board-room.

Recruiting the best talent requires the perfect mix of market knowledge and experience within the search and selection process. Our experienced multi-lingual consultants have a deep understanding of your market segment and have built exceptional reputations within them. We have a strong track record of success, recruiting for commercial & R&D positions and are always on the lookout to partner with innovative companies offering disruptive technologies into the scientific industry.

Besides quality, knowledge and results, the characteristics that really sets us aside from the competition is the way we deliver our service – day in day out. Genuine love and passion for what we do, the wish to help people and the drive to succeed.

Please get in touch if you are searching for a strong recruitment partner.

SRC-Search

Overschiestraat 63
1062 XD Amsterdam
The Netherlands
www.src-search.com



Johann de Bruyn
CEO

+27 82 922 2218

johann.db@task.org.za

TASK Research International

5th Floor, Julius Centre,
UMC Utrecht
Heidelberglaan 100
3584 CX Utrecht
The Netherlands
www.task.org.za

TASK Research International

TASK Research International (TASK) is a multi-national, multi-site clinical research institute committed to improving global health through testing and progressing novelty medicines, vaccines and diagnostics in various medical and therapeutic areas. TASK is capable of providing world class clinical trial services with cost-efficient, timeous and accurate outcomes for Sponsors. This is achieved through the dedicated Phase I unit in Utrecht in collaboration with UMC Utrecht, as well as 6 Clinical sites in South Africa offering Phase I – IV trial services from protocol development through to statistical analysis.

The first clinical trial conducted by TASK was in 2005, and to date the company has completed more than 100 projects for top international academic, government and private institutions and Sponsors. TASK is a partner in the biggest Tuberculosis (TB) consortium in history, that has the ambitious goal of creating a new TB regiment. The grant from the Public and Private Sector is worth €180m.

<https://www.unite4tb.org/>

In addition, the company has a Research Academy focussed on educating and training the next generation of clinical researchers through curriculum development of various clinical trial related training courses.

THINK
INNOVATION
THINC.
HEALTHCARE



Gerdi Janssen

Sr. Business Developer

+31 6 3111 8638

g.janssen-4@umcutrecht.nl

THINC. Healthcare

The number of medical innovations introduced to the market is overwhelming. How do we ensure these innovations reach the patient, are effective in improving healthcare outcomes and fit with complex care processes?

The Healthcare Innovation Center (THINC.), part of UMC Utrecht, offers short-cycle science as a service to entrepreneurs and healthcare innovation companies. With a multidisciplinary team, we evaluate your innovation regarding cost-effectiveness, usability, and feasibility. We also provide expert methodological advice. This is all based on contract research. We have access to patients, healthcare professionals, - costs, - data and test environments. Our products result in effective patient-tailored innovations, well-informed professionals and highly-convinced investors. Companies that are considering coming to Europe or the Netherlands, our services also offer insight for successful market entry.

Clients we serve:

Philips, Regenexx, Phoenix Diagnostics, Jinshan, Oncode Institute, Untire (TiredofCander), UMC Utrecht, OLVG, Haermonics, Minddistrict, Diabetesfonds, GGZ Centraal, Prolira, Digidok, PCAVision.



THINC. Healthcare

Heidelberglaan 100

3584 CX Utrecht

The Netherlands

www.thinc.healthcare



Jan van der Wel

CEO

+31 6 5573 3533

jan.van.der.wel@tnl.group

TNL

TNL carries out highly sophisticated research and development projects. We offer systems engineering, programmable logic, and application development services, as well as embedded and non-embedded electronics design and development. We are specialized in high-speed data acquisition and control systems.

We develop technology for semiconductor manufacturing and defense and security for companies, research institutes and government agencies such as the U.S. Department of Defense. Current projects include electron-beam lithography for customized microelectronics and near-field metrology.

In a consortium with – amongst others – Delft University of Technology and Delmic we are developing an innovative electron microscope, the FAST-EM. It scans with 64 simultaneous electron beams, making the device up to a hundred times faster than a regular single beam scanning electron microscope.

We are a knowledge leader in the field of FPGAs (programmable chips) and programmable logic. Using FPGAs allows you to release your creativity, while the results of new ideas can be easily tested in practice. We use a unique approach that involves repeatable, largely automated development and testing steps.

TNL – Technology for High-Tech and Big Science



Head office Technolution

Burgemeester
Jamessingel 1
2803 WV Gouda
The Netherlands

TNL (the U.S. subsidiary of Technolution)

PO Box 1201 North Market
Street, Suite 111
Wilmington, DE 19801
USA
<https://www.tnl.group>



Sandra Eikhout

Director Market TNO
Healthy Living & Work
+31 6 1374 6725
sandra.eikhout@tno.nl

TNO

TNO; Netherlands Organization for Applied Scientific Research, is an independent Dutch research organization based in Netherlands focused on research in applied science. Targeted innovation is what we stand for. We develop knowledge not for its own sake, but for practical application in day to day life and for future innovations which can improve the quality of living.

TNO Healthy Living & Work is dedicated to accelerate and de-risk up drug development and improve patients' lives. For this, we collaborate with partners from industry, academia, regulators, OEMs and other stakeholders. Projects can be initiated on the basis of fee for service (contract research), public-private partnerships, consulting services and EU projects.

In Life Science and Health, TNO is active in preclinical and early clinical research and digital health with translational models, technologies and scientific research that help drug and food developers investigate the efficacy and safety of their products more effectively.

TNO continuously develops and improves its knowledge position, tools and research portfolio, giving us many new insights into e.g. disease mechanisms, new targets and biomarkers, organ crosstalk, ADME, DMPK, etc.



TNO

Sylviusweg 71
2333 BE Leiden
The Netherlands
www.tno.nl



University Medical Center Groningen



Bart Scheerder

Business Developer

+31 6 1497 7343

b.scheerder@umcg.nl

The University Medical Center Groningen (UMCG) was founded in 1797 and is one of Europe's largest academic hospitals. It is part of the University of Groningen (ARWU #66 / THE #75). Our 13.000 dedicated professionals deliver excellence in patient care, research, education and training, and innovation. Together, we push boundaries for a sustainable future of health.



Wietske Degen

Head Sustainable

Consortia & Alliances

+31 6 1517 7106

w.t.a.degen@rug.nl

UMCG is well-known for its cohort studies, of which a catalogue can be found on our website. The largest biobank and cohort study is Lifelines, an ongoing, three generation, population-based study including over 165.000 participants. At the European Research Institute for the Biology of Ageing (ERIBA) 11 world-class research groups focus on mechanisms that result in loss of cells with age and decline in function of old cells and tissues. With the foundation of the Aletta Jacobs School of Public Health (aletta.rug.nl), UMCG serves the whole spectrum from fundamental to applied and implementation.



**University Medical
Center Groningen
(UMCG)**

Hanzeplein 1

9713 GZ Groningen

The Netherlands

umcginnovationcenter.org

UMCG is located on Campus Groningen (www.campusgroningen.nl), one of the biggest and fastest growing campuses of the Netherlands. The Campus maintains an inspiring ecosystem where high quality researchers and entrepreneurs work together with policymakers on innovative medtech, devices, nutrition and health, and molecules & materials, and analysis of new pharmaceuticals.



UMC Utrecht, U-TRIAL & THINC Healthcare

U-TRIAL, the Utrecht TRial Innovation ALiance, and THINC Healthcare are both organization within the UMC Utrecht.



Peter Gisberts

Managing Director
U-TRIAL & THINC
Healthcare
+31 6 3111 8537
[p.g.l.gisberts@
umcutrecht.nl](mailto:p.g.l.gisberts@umcutrecht.nl)

The UMC Utrecht is a leading international university medical center generating, testing, sharing, and applying knowledge on health, illness, and health care for the benefit of patients and society.

Since everyone deserves the best possible healthcare, UMC Utrecht always sets the bar high. The result: innovative, cutting-edge medical treatment that meets the healthcare needs of today and the future. We develop our unique knowledge in this respect together with patients, patient organizations, and several partners.

The U-TRIAL department fosters the Clinical TRIAL Eco-system within the UMCU, acting as liaison for PI's towards 3rd parties, and visa versa to accelerate the Number, Quality and Impact of clinical trials executed by the UMC Utrecht. We collaborate strongly with CRO's and Healthcare companies to become established and valued research partners.

THINC, The Healthcare Innovation Center, offers short-cycle science as a service to entrepreneurs and healthcare innovation companies. With a multidisciplinary team, we evaluate your innovation regarding cost-effectiveness, usability, and feasibility.

UMC Utrecht, U-TRIAL & THINC Healthcare

Heidelberglaan 100
3584 CX Utrecht
The Netherlands
www.umcutrecht.nl/en



V I V A R T - X



Dan Jing Wu

CEO & Co-founder
+31 6 2056 4830
dj.wu@vivart-x.com

VivArt-X

VivArt-X is focussing on women’s health. Our lead indication will revolutionize breast reconstructive surgery in women who have undergone breast tissue removal after breast cancer diagnosis.

1 in 7 women will develop breast cancer during her life. The impact of physical and emotional pain of postoperative breast cancer patients is correlated to the reconstruction strategy and recovery time. Therefore, there is an unmet need for an effective breast reconstructive method with patient’s own tissue so that surgeons can restore, reconstruct and regenerate breast tissue predictably with long term potential that contributes to an improved quality of breast cancer patient’s life.

VivArt-X offers a revolutionary synthetic biomaterial to achieve excellent cell engraftment, which results in personalized breast reconstruction and ultimately regeneration.



VivArt-X

De Rondom 70 CE1.30
5612 AP Eindhoven
The Netherlands



Thomas Grosfeld
Director Economic,
Entrepreneurship and
International Affairs
+31 6 5580 8220
grosfeld@vnoncw-mkb.nl

The Confederation of Dutch Industry and Employers, known as VNO-NCW, is the largest employers' organisation in The Netherlands. It has 150 branch organisations and more than 400 individual enterprises as affiliate members, representing a total of over 120,000 companies.

It covers practically all sectors of the Dutch economy: industry, commercial services, construction, the retail trade and the health sector; from the smallest firms to the largest corporates. It represents 80% of companies with more than ten employees and 95% of companies with over 100 employees and all companies in the Netherlands employing more than 500 staff.

In cooperation with governments and other social parties, VNO-NCW strives for an inclusive and sustainable Netherlands, where everyone benefits from increasing prosperity. This requires sustainable economic growth and a high quality business and investment environment.

VNO-NCW represents the interests of its members by active ongoing contacts with the government, politicians, public authorities, trade unions and non-governmental bodies. VNO-NCW sits on numerous government advisory and consultative committees in The Netherlands, in Brussels and in international bodies as the International Labour Organisation and, through the BIAC, in the OECD.



VNO-NCW
Bezuidenhoutseweg 12
2595 AV The Hague
The Netherlands
www.vno-ncw.nl

Official delegation & contact details

Ministry of Economic Affairs &
Climate Policy

Ministry of Health, Welfare and Sport

Netherlands Enterprise Agency | Ministry
of Economic Affairs & Climate Policy

Netherlands Innovation Network

Consulate General of the Kingdom of
the Netherlands in New York

Official delegation

**Ministry of Economic Affairs &
Climate Policy**

PO BOX 20401
2500 EK The Hague
The Netherlands
[www.government.nl/
ministries](http://www.government.nl/ministries)



Micky Adriaansens

Minister for Economic Affairs and
Climate Policy



Heleen Bakker

Director for European and International
Affairs

+31 6 3110 2800
h.e.bakker@minezk.nl



Jeroen Heijs

Deputy Director for Innovation and
Knowledge

+31 6 2507 0276
j.heijs@minezk.nl



Petra van Baak

Senior Advisor Life Sciences & Health

+31 6 3166 2421
p.m.vanbaak@minezk.nl



Danique Koehoorn

Policy Officer Life Sciences & Health

+31 6 2965 6104
a.d.koehoorn@minezk.nl

Official delegation

Ministry of Economic Affairs &
Climate Policy

PO BOX 20401
2500 EK The Hague
The Netherlands
[www.government.nl/
ministries](http://www.government.nl/ministries)



Harald Hanemaaijer

Spokesman of the Minister

+31 6 1594 9016

h.hanemaaijer@minezk.nl



Fieke van Twist

Political Advisor

+31 6 1534 8454

s.j.l.vantwist@minezk.nl

Official delegation

Ministry of Health, Welfare and Sport

PO Box 20350
2500 EJ The Hague
The Netherlands
[www.government.nl/
ministries/vws](http://www.government.nl/ministries/vws)



Ernst Kuipers

Minister for Health, Welfare and Sport



Barbara Goezinne

Vice minister for Health, Welfare and
Sport / Director General curative care

DG CZ@minvws.nl



Karim Mostafi

Spokesperson

+31 6 1568 3822

k.mostafi@minvws.nl



Anja Roest

Senior Advisor International Affairs

+31 6 4671 4694

aj.roest@minvws.nl

Official delegation

Netherlands Enterprise
Agency | Ministry of Economic
Affairs & Climate Policy

PO Box 93144

2509 AC The Hague

The Netherlands

<https://english.rvo.nl>



Sandra Pompe

Senior Project Manager

Economic Missions

+31 6 1152 5837

sandra.pompe@rvo.nl



Contact details

Netherlands Innovation Network

50 Milk Street | 16th Floor |
Boston MA 02109 | USA



Mart Duitemeijer

Attaché for Innovation, Technology &
Science

+1 202 615 7168

Mart@nost-boston.org

Consulate General of the Kingdom of the Netherlands in New York

666 Third Avenue | 19th floor |
New York NY 10017 | USA



Ahmed Dadou

Consul General

+1 646 937 3803

ahmed.dadou@minbuza.nl



Netherlands in
the USA



Barry Nieuwenhuijs

Deputy Consul General

+1 917 903 2207

barry.nieuwenhuijs@minbuza.nl



Edwin Maarseveen


Counselor for Health, Welfare and Sport

+1 202 766 76 92

edwin.maarseveen@minbuza.nl

Publication

Netherlands Enterprise Agency
The Hague, the Netherlands
nlbranding@rvo.nl

 @NLNetherlands
#SolvingGlobalChallengesTogether
#NLinUSA